Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanadelumab for treatment of COVID-19 disease
2020-002472-12Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lanadelumab in coronavirus disease 2019 (COVID-19), sponsored by Radboud University Medical Center. Primary endpoint: Reduction in oxygen need. Started May 2020; status: completed.
02
Drugs
lanadelumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002472-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002472-12.